Bio-Rad Laboratories - Class A opened lower at $382.88, compared with its previous close of $386.00. In the last trading session, the stock traded between $369.40 and $390.00. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Bio-Rad Laboratories - Class A is now worth
$ 49.26
Resulting in a loss of
$ 50.74 (50.74%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-15.52 (-4.02%)
Day High
$390.00
Day Low
$369.40
Day Open
$382.88
Prev Close
$386.00
Volume
1,36,572
1W Return
-2.39%
1M Return
1.62%
3M Return
3.94%
6M Return
51.97%
1Y Return
18.24%
Fundamentals
Market Cap ($ Mn)
8,088
PE Ratio
49.14
PB Ratio
1.45
PEG Ratio
-
ROE
10.99%
ROCE
10.14%
EPS (TTM)
$17.05
Investment Returns
1 Week
-2.39%
1 Month
1.62%
3 Months
3.94%
6 Months
51.97%
9 Months
26.15%
Financials
Quarterly
All values in $ Mn
651.6
Jun 25
653.0
Sep 25
693.2
Dec 25
592.1
Mar 26
651.0
Jun 26
656.4
Sep 26
Updates
6Nov
RBC Capital raises Bio-Rad price target to $440, keeps outperform
RBC Capital raises Bio-Rad price target from $390 to $440. Analyst Dan Leonard maintains Outperform rating. Price target increase reflects updated valuation models.
7 days ago
5Nov
Bio-Rad Labs Q3FY26 Results: Revenue up 0.5% to $656 million
Bio-Rad Labs Q3FY26 revenue rose 0.5% YoY to $656 million, marking first currency-neutral growth of the year. Clinical Diagnostics segment grew 2.7% to $402 million, driven by Quality Systems and Diabetes products. Life Science segment fell 2.8% to $255 million, though ex-Process Chromatography sales rose 2.5%. Non-GAAP gross margin expanded to 54.5%, up 100 bps YoY; non-GAAP EPS was $2.65. Full-year 2026 sales guidance reaffirmed at $2.506 billion to $2.596 billion.
8 days ago
31Aug
Bio-Rad CFO to join fireside chat at Wells Fargo Healthcare Conference
Bio-Rad CFO Roop K. Lakkaraju to speak at Wells Fargo’s 21st Annual Healthcare Conference. Fireside chat scheduled for September 9, 2026, at 3:45 pm Eastern Time. Live webcast and replay available via Bio-Rad’s Investor Relations website. Company reported $2.6 billion in revenues for fiscal year 2025.
